Companies / Santa Cruz Biotechnology / MDM2 (SMP14) FITC
Santa Cruz Biotechnology

MDM2 (SMP14) FITC | Santa Cruz Biotechnology

mouse monoclonal IgG1; MDM2 Antibody (SMP14) is an IgG1 κ mouse monoclonal MDM2 antibody (also designated HdmX antibody or HDM2 antibody) that detects the MDM2 protein of mouse, rat and human origin by WB, IP, IF and IHC(P). MDM2 Antibody (SMP14) is available as both the non-conjugated anti-MDM2 antibody form, as well as multiple conjugated forms of anti-MDM2 antibody, including agarose, HRP, PE, FITC and multiple Alexa Fluor® conjugates. MDM, also designated murine double minute-2 was initially identified as an oncogene in a murine transformation system. The MDM2 protein functions to bind p53 and block p53-mediated transactivation of cotransfected reporter constructs. The MDM2 gene is amplified in a high percentage of human sarcomas that retain wildtype p53 and tumor cells that overexpress MDM2 can tolerate high levels of p53 expression. These findings argue that MDM2 overexpression represents at least one mechanism by which p53 function can be abrogated during tumorigenesis. The MDM2 Antibody (SMP14) is therefore an important reagent for cancer research. p53 is the most commonly mutated gene in human cancer identified to date. Expression of p53 leads to inhibition of cell growth by preventing progression of cells from G1 to S phase of the cell cycle. Most importantly, p53 functions to cause arrest of cells in the G1 phase of the cell cycle following any exposure of cells to DNA-damaging agents.

Reviews


No reviews yet

ABOUT THE COMPANY

Santa Cruz Biotechnology is a world leader in the development of products for the biomedical research market. Over the past 30+ years, the Company has focused on the ongoing development of research antibodies, siRNA and CRISPR Gene editing tools, biochemicals, labware and more recently has expanded into animal health care products. Santa Cruz Biotechnology has the highest commitment to quality and customer service.